Phaseline

Targets › PTGER4

PTGER4 (Prostaglandin E2 receptor EP4 subtype): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 2 Phase 2, 1 Phase 4, 1 Phase 1; Other, Oncology; next expected readout Dec 2026.

Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. (UniProt, P35408)

Open in Phaseline: the race on PTGER4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
HaEmek Medical Center, IsraelDinoprostone
Prostaglandin E2 receptor agonist
PTGER1, PTGER4, PTGER2, PTGER3Phase 4Induction of LaborJan 2027
Ghufran Dhari AwadProstaglandin E1
Prostaglandin E1 receptor agonist
PTGER1, PTGER2, PTGER3, PTGER4Phase 2Accelerated Orthodontic Tooth MovementDec 2026
National Cancer Institute (NCI)TPST-1495
Dual EP2/EP4 antagonist; prostaglandin E2 receptor antagonist
PTGER2, PTGER4Phase 2Colorectal CarcinomaJun 2027
Rottapharm BiotechVorbipiprant (CR6086)
Prostanoid EP4 receptor antagonist
PTGER4Phase 1Refractory Metastatic Colorectal CancerDec 2026

Conditions

Accelerated Orthodontic Tooth Movement (1) Induction of Labor (1) Colorectal Carcinoma (1) Refractory Metastatic Colorectal Cancer (1)

Modalities

small molecule (3), mixed (1)

Companies

Ghufran Dhari Awad (1) HaEmek Medical Center, Israel (1) National Cancer Institute (NCI) (1) Rottapharm Biotech (1)

Related targets

PTGER2 (3) PTGER1 (2) PTGER3 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.